Insider · CIK 0001987188
Mike Kelliher
Files at CAPR (CAPRICOR THERAPEUTICS, INC.), ARDX (ARDELYX, INC.). First filing May 22, 2025, latest Aug 28, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARDX: ARDELYX, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | ARDELYX, INC. | $32k 5,417 shares | -2% | +86% from low-12% from high | |
| 37Weak | ARDELYX, INC. | $59k 14,522 shares | -5% | +27% from low-40% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -5,417 | $5.93 | $32k | 276,741 | Aug 28, 2025 |
| May 20, 2025 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -14,522 | $4.08 | $59k | 282,158 | May 22, 2025 |
| Feb 25, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +136,680 | $0.00 | $0 | 296,680 | Feb 27, 2025 |
| Feb 25, 2025 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +205,019 | $0.00 | $0 | 205,019 | Feb 27, 2025 |
| Jan 2, 2025 | CAPR CAPRICOR THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | CAPR CAPRICOR THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,440 | $0.00 | $0 | 1,440 | Jan 6, 2025 |
| Jan 2, 2025 | CAPR CAPRICOR THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.